User menu

Anemia and transfusions in patients undergoing surgery for cancer.

Bibliographic reference Weber, Randal S ; Jabbour, Nicolas ; Martin, Robert C G. Anemia and transfusions in patients undergoing surgery for cancer.. In: Annals of Surgical Oncology, Vol. 15, no.1, p. 34-45 (2007)
Permanent URL
  1. Krupp NL, Weinstein G, Chalian A, Berlin JA, Wolf P, Weber RS. Validation of a transfusion prediction model in head and neck cancer surgery. Arch Otolaryngol Head Neck Surg 2003; 129:1297–302
  2. Shvarts O, Tsui KH, Smith RB, Kernion JB, Belldegrun A. Blood loss and the need for transfusion in patients who undergo partial or radical nephrectomy for renal cell carcinoma. J Urol 2000; 164:1160–3
  3. Benoist Stéphane, Panis Yves, Pannegeon Virginie, Alves Arnaud, Valleur Patrice, Predictive factors for perioperative blood transfusions in rectal resection for cancer: A multivariate analysis of a group of 212 patients, 10.1067/msy.2001.112068
  4. Elias D, Raynard B, Boige V, Laplanche A, Estphan G, Malka D, Pocard M. Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 2005; 90:220–5
  5. Dunne JR, Gannon CJ, Osborn TM, Taylor MD, Malone DL, Napolitano LM. Preoperative anemia in colon cancer: assessment of risk factors. Am Surg 2002; 68:582–7
  6. Shander A, Knight K, Thurer R, Adamson J, Spence R. Prevalence, outcomes of anemia in surgery: a systematic review of the literature. Am J Med 2004; 116(Suppl 7A):58S–69S
  7. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616–34
  8. Birgegard G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005; 68(Suppl 1):3–11
  9. Voelter V, Schuhmacher C, Busch R, Peschel C, Siewert JR, Lordick F. Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer. Ann Thorac Surg 2004; 78:1037–41
  10. Monk TG, Goodnough LT, Brecher ME, Colberg JW, Andriole GL, Catalona WJ. A prospective randomized comparison of three blood conservation strategies for radical prostatectomy. Anesthesiology 1999; 91:24–33
  11. Lent V, Neuss A. Management of bleeding, transfusion requirement and removal of catheters in transurethral prostate resection. Eur Urol 1997; 32:257–67
  12. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91:2214–21
  13. Lutterbach Johannes, Guttenberger Roland, Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx, 10.1016/s0360-3016(00)01382-1
  14. Martin-Loeches M, Orti RM, Asins E, Llixiona J. The prognostic implications of anaemia in the outcome of patients with early stages of uterine cervix carcinoma. Arch Gynecol Obstet 2003; 267:121–5
  15. Macdonald G, Influence of Anaemia in Patients with Head and Neck Cancer Receiving Adjuvant Postoperative Radiotherapy in the Grampian Region, 10.1016/j.clon.2003.09.009
  16. Yovino Susannah, Kwok Young, Krasna Mark, Bangalore Madan, Suntharalingam Mohan, An association between preoperative anemia and decreased survival in early-stage non–small-cell lung cancer patients treated with surgery alone, 10.1016/j.ijrobp.2004.12.038
  17. Saibishkumar Elantholi P., Patel Firuza D., Ghoshal Sushmita, Kumar Vinay, Karunanidhi Gunaseelan, Sharma Suresh C., Results of salvage radiotherapy after inadequate surgery in invasive cervical carcinoma patients: A retrospective analysis, 10.1016/j.ijrobp.2005.04.002
  18. van de Pol SM, Doornaert PA, de Bree R, Leemans CR, Slotman BJ, Langendijk JA. The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. Oral Oncol 2006; 42:131–8
  19. Cella D. Quality of life and clinical decisions in chemotherapy-induced anemia. Oncology (Williston Park) 2006; 20:25–8
  20. Blohmer JU, Dunst J, Harrison L, et al. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 2005; 68(Suppl 1):12–21
  21. Dougenis D, Patrinou V, Filos KS, Theodori E, Vagianos K, Maniati A. Blood use in lung resection for carcinoma: perioperative elective anaemia does not compromise the early outcome. Eur J Cardiothorac Surg 2001; 20:372–7
  22. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409–17
  23. Carson JL, Terrin ML, Barton FB, et al. A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion 1998; 38:522–9
  24. Bush RL, Pevec WC, Holcroft JW. A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. Am J Surg 1997; 174:143–8
  25. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003; 289:959–62
  26. Goodnough LT. Risks of blood transfusion. Crit Care Med 2003; 31:S678–86
  27. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002; 42:537–48
  28. Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993–2001. Vox Sang 2003; 84:274–86
  29. Seed CR, Kiely P, Keller AJ. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005; 35:592–8
  30. Kleinman Steven, Chan Penny, Robillard Pierre, Risks associated with transfusion of cellular blood components in canada, 10.1053/tmrv.2003.50009
  31. O’Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007; 47:316–25
  32. Marcucci C, Madjdpour C, Spahn DR. Allogeneic blood transfusions: benefit, risks and clinical indications in countries with a low or high human development index. Br Med Bull 2004; 70:15–28
  33. Cruz JR, Perez-Rosales MD, Zicker F, Schmunis GA. Safety of blood supply in the Caribbean countries: role of screening blood donors for markers of hepatitis B and C viruses. J Clin Virol 2005; 34 Suppl 2:S75–80
  34. Imarengiaye CO, Enosolease ME, Iribhogbe PE, Ehigiegba AE. Risk of transfusion-transmitted hepatitis C virus in a tertiary hospital in Nigeria. Public Health 2006; 120:274–8
  35. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, Will RG. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417–21
  36. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527–9
  37. Wilson K, Ricketts MN. A third episode of transfusion-derived vCJD. Lancet 2006; 368:2037–9
  38. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. Vox Sang 2006; 91:348
  39. Dellinger EP, Anaya DA. Infectious and immunologic consequences of blood transfusion. Crit Care 2004; 8(Suppl 2):S18–23
  40. Montgomery SP, Brown JA, Kuehnert M, et al. Transfusion-associated transmission of West Nile virus, United States 2003 through 2005. Transfusion 2006; 46:2038–46
  41. Madjdpour C, Heindl V, Spahn DR. Risks, benefits, alternatives and indications of allogenic blood transfusions. Minerva Anestesiol 2006; 72:283–98
  42. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts—blood transfusion. N Engl J Med 1999; 340:438–47
  43. AuBuchon James P., Safety of the Blood Supply in the United States: Opportunities and Controversies, 10.7326/0003-4819-127-10-199711150-00009
  44. Brittenham GM, Klein HG, Kushner JP, Ajioka RS. Preserving the national blood supply. Hematology (Am Soc Hematol Educ Program) 2001:422–432
  45. Nuttall GA, Stehling LC, Beighley CM, Faust RJ. Current transfusion practices of members of the American Society of Anesthesiologists: a survey. Anesthesiology 2003; 99:1433–43
  46. Stainsby D, Williamson L, Jones H, Cohen H. 6 Years of shot reporting–its influence on UK blood safety. Transfus Apher Sci 2004; 31:123–31
  47. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006:CD005033
  48. Stainsby D. ABO incompatible transfusions—experience from the UK Serious Hazards of Transfusion (SHOT) scheme Transfusions ABO incompatible. Transfus Clin Biol 2005; 12:385–8
  49. Williamson L M, Lowe S, Love E M, Cohen H, Soldan K, McClelland D B L, Skacel P, Barbara J A J, Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports, 10.1136/bmj.319.7201.16
  50. Sazama K. Transfusion errors: scope of the problem, consequences, and solutions. Curr Hematol Rep 2003; 2:518–21
  51. Pagliaro P, Rebulla P. Transfusion recipient identification. Vox Sang 2006; 91:97–101
  52. Baele PL, De Bruyere M, Deneys V, et al. Bedside transfusion errors. A prospective survey by the Belgium SAnGUIS Group. Vox Sang 1994; 66:117–21
  53. Dzik W. H., Technology for Enhanced Transfusion Safety, 10.1182/asheducation-2005.1.476
  54. Janatpour K, Holland PV. Noninfectious serious hazards of transfusion. Curr Hematol Rep 2002; 1:149–55
  55. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev 2001; 15:69–83
  56. Moore SB. Transfusion-related acute lung injury (TRALI): clinical presentation, treatment, and prognosis. Crit Care Med 2006; 34:S114–7
  57. Zoon KC. U.S. Food and Drug Administration Center for Biologics Evaluation and Research Alert: Transfusion Related Acute Lung Injury. Available at: . 2002
  58. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101:454–62
  59. Kopko PM. Leukocyte antibodies and biologically active mediators in the pathogenesis of transfusion-related acute lung injury. Curr Hematol Rep 2004; 3:456–61
  60. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002; 287:1968–71
  61. Higgins MJ, Blackall DP. Transfusion-associated graft-versus-host disease: a serious residual risk of blood transfusion. Curr Hematol Rep 2005; 4:470–6
  62. Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973; 5:253–9
  63. Vamvakas EC. WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. Transfusion 2003; 43:963–73
  64. Fergusson D, Khanna MP, Tinmouth A, Hebert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth 2004; 51:417–24
  65. Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993; 80:427–32
  66. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97:1180–95
  67. Tachibana M, Tabara H, Kotoh T, et al. Prognostic significance of perioperative blood transfusions in resectable thoracic esophageal cancer. Am J Gastroenterol 1999; 94:757–65
  68. Asahara T, Katayama K, Itamoto T, et al. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg 1999; 23:676–80
  69. Makino Y, Yamanoi A, Kimoto T, El-Assal ON, Kohno H, Nagasue N. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am J Gastroenterol 2000; 95:1294–300
  70. Hyung WJ, Noh SH, Shin DW, Huh J, Huh BJ, Choi SH, Min JS. Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann Surg Oncol 2002; 9:5–12
  71. Pysz M. Blood transfusions in breast cancer patients undergoing mastectomy: possible importance of timing. J Surg Oncol 2000; 75:258–63
  72. Santin AD, Bellone S, Parrish RS, et al. Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix. Gynecol Obstet Invest 2003; 56:28–34
  73. Dresner SM, Lamb PJ, Shenfine J, Hayes N, Griffin SM. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur J Surg Oncol 2000; 26:492–7
  74. Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328:1372–6
  75. Busch OR, Hop WC, Marquet RL, Jeekel J. Blood transfusions and local tumor recurrence in colorectal cancer. Evidence of a noncausal relationship. Ann Surg 1994; 220:791–7
  76. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12:1859–67
  77. van de Watering LM, Brand A, Houbiers JG, Klein Kranenbarg WM, Hermans J, van de Velde C. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. Br J Surg 2001; 88:267–72
  78. Ho J, Sibbald WJ, Chin-Yee IH. Effects of storage on efficacy of red cell transfusion: when is it not safe? Crit Care Med 2003; 31:S687–97
  79. Offner PJ. Age of blood: does it make a difference? Crit Care 2004; 8 (Suppl 2):S24–6
  80. Offner PJ, Moore EE, Biffl WL, Johnson JL, Silliman CC. Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg 2002; 137:711–6; discussion 716–7
  81. Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg 1999; 178:570–2
  82. Hebert PC, Chin-Yee I, Fergusson D, Blajchman M, Martineau R, Clinch J, Olberg B. A pilot trial evaluating the clinical effects of prolonged storage of red cells. Anesth Analg 2005; 100:1433–8
  83. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100:2303–20
  84. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40:2201–16
  85. Rodgers GM 3rd, Cella D, Chanan-Khan A, et al. Cancer- and treatment-related anemia. J Natl Compr Canc Netw 2005; 3:772–89
  86. Weber RS. A model for predicting transfusion requirements in head and neck surgery. Laryngoscope 1995; 105:1–17
  87. Goodnough LT. Autologous blood donation. Crit Care 2004; 8(Suppl 2):S49–52
  88. Popovsky MA, Whitaker B, Arnold NL. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion 1995; 35:734–7
  89. Tretiak R, Laupacis A, Riviere M, McKerracher K, Souetre E. Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group. CMAJ 1996; 154:1501–8
  90. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81:2–10
  91. Shaheen SP 2nd, Lichtiger B. Autologous deposit of blood by oncology patients: an evaluation of actual use and wastage. Ann Surg Oncol 1995; 2:457–61
  92. Nath A, Pogrel MA. Preoperative autologous blood donation for oral and maxillofacial surgery: an analysis of 913 patients. J Oral Maxillofac Surg 2005; 63:347–9
  93. Jamnicki M, Kocian R, van der Linden P, Zaugg M, Spahn DR. Acute normovolemic hemodilution: physiology, limitations, and clinical use. J Cardiothorac Vasc Anesth 2003; 17:747–54
  94. Segal JB, Blasco-Colmenares E, Norris EJ, Guallar E. Preoperative acute normovolemic hemodilution: a meta-analysis. Transfusion 2004; 44:632–44
  95. Svenmarker S, Engstrom KG. The inflammatory response to recycled pericardial suction blood and the influence of cell-saving. Scand Cardiovasc J 2003; 37:158–64
  96. Andersson I, Tylman M, Bengtson JP, Bengtsson A. Complement split products and pro-inflammatory cytokines in salvaged blood after hip and knee arthroplasty. Can J Anaesth 2001; 48:251–5
  97. Hansen Ernil, Tumor Cells in Blood Shed From the Surgical Field, 10.1001/archsurg.1995.01430040049007
  98. Perseghin P, Vigano M, Rocco G, Della Pona C, Buscemi A, Rizzi A. Effectiveness of leukocyte filters in reducing tumor cell contamination after intraoperative blood salvage in lung cancer patients. Vox Sang 1997; 72:221–4
  99. Gray CL, Amling CL, Polston GR, Powell CR, Kane CJ. Intraoperative cell salvage in radical retropubic prostatectomy. Urology 2001; 58:740–5
  100. Martin RCG, Wellhausen SR, Moehle DA, Martin AW, McMasters KM. Evaluation of intraoperative autotransfusion filtration for hepatectomy and pancreatectomy. Ann Surg Oncol 2005; 12:1017–24
  101. Hansen E, Bechmann V, Altmeppen J. Intraoperative blood salvage in cancer surgery: safe and effective? Transfus Apher Sci 2002; 27:153–7
  102. Freischlag JA. Intraoperative blood salvage in vascular surgery—worth the effort? Crit Care 2004; 8(Suppl 2):S53–6
  103. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts–blood conservation. N Engl J Med 1999; 340:525–33
  104. PROCRIT® (Epoetin alfa) Prescribing Information. Raritan, NJ: Ortho Biotech Products L.P.; 2007
  105. Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study. Laryngoscope 2002; 112:1221–9
  106. Kosmadakis N, Messaris E, Maris A, Katsaragakis S, Leandros E, Konstadoulakis MM, Androulakis G. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study. Ann Surg 2003; 237:417–21
  107. ARANESP® (Darbepoetin alfa) Prescribing Information. Thousand Oaks, CA: Amgen, Inc.; 2007
  108. EPOGEN® (Epoetin alfa) Prescribing Information. Thousand Oaks, CA: Amgen, Inc.; 2007
  109. Hollender A, Bjoro T, Otto Karlsen K, Kvaloy SO, Nome O, Holte H. Vitamin D deficiency in patients operated on for gastric lymphoma. Scand J Gastroenterol 2006; 41:673–81
  110. Roviello F, Fotia G, Marrelli D, De Stefano A, Macchiarelli R, Pinto E. Iron deficiency anemia after subtotal gastrectomy for gastric cancer. Hepatogastroenterology 2004; 51:1510–4
  111. Knap MM, Lundbeck F, Overgaard J. Early and late treatment-related morbidity following radical cystectomy. Scand J Urol Nephrol 2004; 38:153–60
  112. Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005; 11:14–23
  113. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22:1301–7
  114. Spahn DR, Kocian R. Artificial O2 carriers: status in 2005. Curr Pharm Des 2005; 11:4099–114
  115. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003; 43:668–76
  116. Jabbour N (ed.). Transfusion-Free Medicine, Surgery. Malden, MA: Blackwell Publishing, Inc.; 2005
  117. Weber RS, Byers RM, Robbins KT, et al. Electrosurgical dissection to reduce blood loss in head and neck surgery. Head Neck 1989; 11:318–24
  118. Shander A, Goodnough LT. Objectives and limitations of bloodless medical care. Curr Opin Hematol 2006; 13:462–70
  119. Levi M. Critical bleeding in surgery: conventional therapy and new prospects. Minerva Anestesiol 2004; 70:267–71
  120. Kokoszka A, Kuflik P, Bitan F, Casden A, Neuwirth M. Evidence-based review of the role of aprotinin in blood conservation during orthopaedic surgery. J Bone Joint Surg Am 2005; 87:1129–36
  121. Royston D, Chhatwani A. Safety aspects of aprotinin therapy in cardiac surgery patients. Expert Opin Drug Saf 2006; 5:539–52